Biogen Inc. reported second-quarter adjusted earnings per share of $3.60, surpassing the consensus estimate of $2.96, while total revenue reached $2.736 billion, exceeding expectations of $2.458 billion. Driven by strong performance across its Alzheimer's and rare disease portfolio, the company raised its fiscal 2026 adjusted earnings per share guidance to a range of $15.85-$16.85, up from the previous outlook of $15.25-$16.25. This revised guidance significantly outpaces the analyst consensus estimate of $12.83, signaling robust profitability expectations for the coming fiscal year.

The revenue increase of 3% on a reported basis (2% on a constant currency basis) was fueled by growth in key products including Leqembi, Skyclarys, and Zurzuvae, alongside contributions from the recently acquired Apellis portfolio. Management attributes the upward revision in guidance to sustained demand for high-dose Spinraza regimens and the successful integration of new assets. Biogen also announced full-year total revenue is expected to grow by a mid-single-digit percentage in FY26 compared to FY25.

Product Performance Highlights

The following table details the revenue performance of Biogen's key therapeutic assets during the second quarter:

Spinraza revenue rose 2% year-over-year as conversion to the high-dose regimen proceeded ahead of expectations in all launched geographies. Conversely, Vumerity revenue declined 7% due to inventory dynamics, though the first half showed 7% year-over-year growth. Leqembi generated $184 million in total revenue, with approximately $97 million from U.S. in-market sales.

Strategic Acquisitions and Pipeline

Biogen completed the acquisition of Apellis, adding Syfovre and Empaveli to its portfolio. These assets contributed $128 million in revenue during the quarter and are projected to grow at mid- to high-teens rates through 2028. Additionally, Skyclarys, acquired via the Reata deal, saw revenues jump 29% to $168 million.

In pipeline developments, Biogen shared Phase 2 data for BIIB091 in relapsing-remitting multiple sclerosis, achieving proof-of-concept. The company also exercised an option with Ionis Pharmaceuticals Inc. to obtain a worldwide exclusive license for BIIB147, an investigational antisense oligonucleotide targeting ALS, paying a one-time fee of $15 million.

What the Numbers Show

The divergence between Biogen’s new guidance midpoint of approximately $16.35 and the analyst consensus of $12.83 suggests the market had underestimated the company’s near-term earnings potential. The uniform uplift of $0.60 in both the lower and upper bounds of the guidance indicates confidence across all modeled scenarios. Barclays maintained an Equal-Weight rating but raised its price target from $185 to $200, reflecting improved sentiment. Biogen shares traded higher, up 1.99% to $209.70 on Wednesday.

Biogen (NASDAQ: BIIB) has lowered its fiscal year 2026 adjusted earnings per share (EPS) guidance, signaling a more conservative outlook for the upcoming period. The company revised its full-year EPS forecast downward from a previous range of $14.25 to $15.25 to a new range of $12.00 to $13.00. This updated guidance now sits below the consensus analyst estimate of $12.83, indicating that market expectations were not met by the company’s latest internal projections.

The reduction in guidance reflects a material shift in Biogen’s financial trajectory for FY26. By cutting the midpoint of its EPS range by approximately $1.00 per share, the company is acknowledging headwinds or operational challenges that impact profitability expectations. The new upper bound of $13.00 is still marginally above the street estimate of $12.83, but the lower bound of $12.00 introduces significant downside risk relative to prior expectations.

Guidance Revision Details

The following table outlines the change in Biogen’s fiscal year 2026 adjusted EPS guidance compared to the previous outlook and current analyst estimates:

The revision underscores the importance of monitoring Biogen’s upcoming quarterly reports for further clarity on the drivers behind this downgrade. Investors will be closely watching whether the company can stabilize its earnings power within the new, narrower band of $12.00 to $13.00.